Safety profile of FLT3 inhibitors in acute myeloid leukemia: a systematic review and meta-analysis of adverse events - PubMed
11 hours ago
- #acute myeloid leukemia
- #safety profile
- #FLT3 inhibitors
- FLT3 inhibitors (midostaurin, gilteritinib, quizartinib) are used in FLT3-mutated AML, which affects ~30% of AML patients and is linked to poor prognosis.
- A systematic review and meta-analysis of 7 RCTs (2,409 patients) found that FLT3 inhibitors do not significantly increase adverse event (AE) risk compared to standard treatments.
- The most common AEs were blood/lymphatic system disorders (58.4% FLT3 inhibitor-related), gastrointestinal disorders, pyrexia, elevated ALT/AST, and headache.
- No major differences in AE risk were observed among midostaurin, gilteritinib, and quizartinib, except for higher ALT increase risk with gilteritinib (RR=2.40).
- Future studies should stratify safety outcomes by patient demographics and include long-term follow-up for better safety assessment.